

Joe Lombardo
Governor

Richard Whitley, MS
Director



DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, June 12, 2025, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																											
1. Closed Executive Session																													
A. Call to Order and Roll Call	<p>Chairperson Mark Decerbo called the meeting to order at 1:05 PM on June 12, 2025.</p> <p>Chairperson Decerbo took the roll.</p> <table><thead><tr><th></th><th>Present</th><th>Absent</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none">• Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director• Brown, Antonio, Chief of Pharmacy & DME• Palomino, Bonnie, Pharmacy Services Manager• Flowers, Ellen, Social Services Program Specialist II• Cabrera, Donna, Program Officer I• Vannucci, Jessica, DME Manager <p>NMAP Staff Present were as follows:</p> <ul style="list-style-type: none">• Johnson, Tory, Health Program Manager II
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none"> • Deoliveira, Brittany, Pharm.D., Clinical Account Manager • Mishra, Raj, Pharm.D., Clinical Account Manager • Czechowski, Jessica, Pharm.D., Director, Clinical Account Services • Martinez, Chris, Sr. Business Analyst • Perez, Melissa, Sr. Business Analyst
<p>B. Financial Review of Drug Classes with Proposed Changes</p>	<p>Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the Financial Review of Drug classes with proposed changes up for review.</p> <p>Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</p> <p>Dr. Deoliveira presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Targeted Immunomodulator <p>Dr. Deoliveira presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Cholinesterase Inhibitors • Beta-Blockers 	

	<ul style="list-style-type: none"> • Phosphodiesterase Type 4 Inhibitors or Combination • Incretin Mimetics and Combinations • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)- Oral • Rapid-Acting Insulins • Short-Intermediate Acting Insulins • Long-Acting Insulins • Pre-Mixed Insulin Combinations <p>Dr. Deoliveira presented the financial review of the new drug classes being reviewed for proposed addition, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Antivirals, COVID-19 • Steroids, Topical Low • Steroids, Topical Medium • Steroids, Topical High • Steroids, Topical Very High 																												
2. Open Public Meeting																													
A. Call to Order and Roll Call	<p>Chairperson Decerbo called the meeting to order at 2:05 PM on June 12, 2025.</p> <p>A quorum was present.</p> <p>Chairperson Decerbo took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> • Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director • Brown, Antonio, Chief of Pharmacy & DME • Palomino, Bonnie, Pharmacy Services Manager • Flowers, Ellen, Social Services Program Specialist II • Cabrera, Donna, Program Officer I • Vannucci, Jessica, DME Manager <p>NMAP Staff Present were as follows:</p>
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<ul style="list-style-type: none">Johnson, Tory, Health Program Manager II <p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none">Deoliveira, Brittany, Pharm.D., Clinical Account ManagerMishra, Raj, Pharm.D., Clinical Account ManagerCzechowski, Jessica, Pharm.D., Director, Clinical Account ServicesMartinez, Chris, Sr. Business AnalystPerez, Melissa, Sr. Business Analyst <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured</p>																
B. Approval for previous Meeting Minutes from March 20, 2025.	<p>Board Member Sapandeep Khurana moved to approve the meeting minutes and Board Member Elizabeth Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

	<ul style="list-style-type: none"> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
C. Public Comments	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
D. Status Update by DHCFP	<p>Medicaid Pharmacy Director, Dr. Keiko Duncan, provided an announcement.</p> <ul style="list-style-type: none"> • We have officially closed out our legislative session for this year, which for anybody following was quite an extensive six months. There were lots of pharmacy bills that were on the table. There was a very large Nevada Health Authority reorganization bill as well. So, I will start there. The Nevada Health Authority was approved and signed by the governor. That is going to essentially split up our current Department of Health and Human Services into essentially all things health on one side. So that includes Nevada Medicaid and the exchange, the employee benefit and all of that. And that would all be under the Nevada Health Authority. Really, no changes for our board here. We are just going to keep on doing what we do, but I just wanted to make sure you were all aware. So very, very exciting and historic for Nevada Healthcare. • We also introduced a budget that was approved, and a part of that budget did indicate that Medicaid would be moving to a Single Preferred Drug List (PDL) or what we call a “Single PDL”. 	

	<p>So, what that means is that the Fee-For-Service (FFS) pharmacy benefit, as well as each of our Managed Care Organization (MCO's) pharmacy benefits, would all be utilizing one singular unified PDL. So right now, there are four MCO's and FFS and there are five individual PDL's that are all out there for our recipients. And so, this move would unify that benefit. It would help some with care coordination and ensuring that all of our recipients receive a very unified benefit. So, with that being said, over the next six months or so, that project will be lifted. This board will be participating in any of those PDL changes that we might make to get to that point.</p> <p>And certainly, in upcoming meetings, we will make further announcements as to where we are at with that, how it is going and any conversations we need to bring to our board members here to discuss.</p> <ul style="list-style-type: none"> • We are still looking to recruit for both of our pharmacy boards. So that is this one the Silver State Scripts Board, that determines our preferred and non-prefer drug list as well as the DUR Board, which determines our clinical criteria. So, we are looking for all sorts of healthcare professionals. Anything from physicians, PA, APRN to pharmacists, if you know anybody, please, please, please do pass that along. You can always find the information on our Nevada Medicaid website or e-mail us at rxinfo@dncfp.nv.org. 	
E. Status Update by NMAP	<p>Health Program Manager, Tory Johnson, provided an announcement.</p> <ul style="list-style-type: none"> • A request for proposal through state purchasing for a new PBM was recently approved through the most recent BOE meeting. Effective July 1st of this year, our PBM vendor will be changing to Ramsell. 	
3. Clinical Presentations		

A. For Possible Action: Discussion and possible adoption of Targeted Immunomodulator.										
I. <u>Public comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Nick Trombold, Associate Director with Alexion Pharmaceuticals, Health Economics Outcomes Research.</p> <p>Public comment was provided by Amy Hale, Pharmacist and Principal Scientific Account Lead with Johnson and Johnson Innovative Medicine.</p> <p>Public comment was provided by Mandeep Sohal, Pharmacist with Teva in Medical Affairs.</p>									
II. Drug class review presentation by Prime.	<p>Dr. Deoliveira discussed Stelara® (ustekinumab) and biosimilars, Remicade® (infliximab) and biosimilars, Actemra® (tocilizumab) and biosimilars and Arcalyst®. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>									
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Joseph Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime, and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.							
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>							

	<ul style="list-style-type: none"> • Kate Ward, Pharm.D., Vice Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
IV. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended adding the Stelara® biosimilars Pyzchiva® and Yesintek® to the PDL, while shifting the reference product “Stelara®” from preferred to non-preferred.</p> <p>She also recommends placing the unbranded Stelara® product (ustekinumab) as well as the other Stelara® biosimilar products as non-preferred at this time, including: Otulfi®, Selarsdi®, Staqeyma®, ustekinumab-aekn, and ustekinumab-ttwe. Of note, Wezlana® will not be placed due to non-participation in the Medicaid Drug Rebate Program (MDRP).</p> <p>Additionally, we recommend adding Zymfentra® (a SQ biosimilar for Remicade®) to the Non-Preferred Drug List.</p> <p>Dr. Deoliveira also recommend placing Tyenne® and Tofidence® (biosimilars to Actemra®) as non-preferred; keeping Actemra® reference product as preferred at this time and lastly, we recommend placing Arcalyst® as non-preferred.</p>	
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <p style="text-align: right;">Yes No Abst.</p>	

	<ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Kate Ward, Pharm.D., Vice Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
B. For Possible Action: Discussion and possible adoption of Alzheimer's Agents: Cholinesterase Inhibitors.		
I. <u>Public comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided.</p>	
II. Drug class review presentation by Prime.	<p>Dr. Deoliveira discussed Zunveyl®. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>	
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalaz seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

		<div> <div>YesNoAbst.</div> <div> <div>• Mark Decerbo, Pharm.D., Chair</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Kate Ward, Pharm.D., Vice Chair</div> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div> </div> <div> <div>• Joseph Adashek, MD</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Mark Crumby, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Elizabeth Gonzalez, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Sapandeep Khurana, MD</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Leana Ramirez, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Aditi Singh, MD</div> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div> </div> </div>	
IV.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended moving rivastigmine from non-preferred to preferred, and defining this as both the capsule and the transdermal patch.</p> <p>Moving the branded version of the rivastigmine patch (Exelon®) from preferred to non-preferred.</p> <p>Defining the current galantamine product as both the tablet and solution on the Non-Preferred Drug List.</p> <p>Placing Zunveyl® (benzgalantamine) on the Non-Preferred Drug List and removing Razadyne ER® branded product from the PDL, as this product has been discontinued.</p>	
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Leana Ramirez seconded the motion.</p> <div> <div>YesNoAbst.</div> <div> <div>• Mark Decerbo, Pharm.D., Chair</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Kate Ward, Pharm.D., Vice Chair</div> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div> </div> <div> <div>• Joseph Adashek, MD</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Mark Crumby, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Elizabeth Gonzalez, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Sapandeep Khurana, MD</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Leana Ramirez, Pharm.D.</div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> </div> <div> <div>• Aditi Singh, MD</div> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div> </div> </div>	

C. For Possible Action: Discussion and possible adoption of Beta-Blockers .																																						
I. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																					
II. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
IV. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended removing Coreg CR from the PDL, as it is no longer participating in the MDRP.</p> <p>She recommends adding Hemangeol® (the branded propranolol solution) to the PDL.</p>																																					

	Moving the combination product metoprolol/HCTZ® from preferred to non-preferred and placing Inderal LA®, Inderal XL®, and InnoPran XL® (all extended-release propranolol products) as non-preferred.																																					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
D. For Possible Action: Discussion and possible adoption of Phosphodiesterase Type 4 Inhibitors or Combination.																																						
I. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member																																					

	approve clinical/therapeutic equivalency of agents in class.	<p>Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
IV.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended moving Ohtuvayre® from preferred to non-preferred.																																					
V.	Board Member Comments	Comment was provided by Board Member Gonzalez.																																					
VI.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>									
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				

	<ul style="list-style-type: none">• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																					
E. For Possible Action: Discussion and possible adoption of Incretin Mimetics and Combinations.																																						
I. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																					
II. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			

IV.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended placing exenatide generic product as non-preferred.																																					
V.	Board Member Comments	Comment was provided by Board Member Khurana.																																					
VI.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
F.	For Possible Action: Discussion and possible adoption of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)- Oral.																																						
I.	<u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					

II.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
IV.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended removing Sprix® from the PDL, as it is no longer participating in the MDRP.</p> <p>She recommends adding ibuprofen chew tab and ibuprofen/APAP to the PDL.</p> <p>Switching naproxen suspension from preferred to non-preferred and placing the following products as non-preferred:</p> <ul style="list-style-type: none">• Arthrotec®• Celebrex®• Ibuprofen/famotidine combination product• Indomethacin oral suspension and rectal suppository																																					

	<ul style="list-style-type: none">Tolmetin sodium (capsule and tablet)																																					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
G. For Possible Action: Discussion and possible adoption of Rapid-Acting Insulins.																																						
I. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.																																					

equivalency of agents in class.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
IV. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended moving Apidra® and Apidra Solostar® from preferred to non-preferred.</p> <p>She also recommended moving branded Humalog® products from preferred to non-preferred, and instead preferring the generic products (insulin lispro) – including the insulin lispro Junior Kwikpen.</p> <p>She also recommended moving branded Novolog® products from preferred to non-preferred, and instead preferring the generic products (insulin aspart).</p> <p>She also recommended all Fiasp® products (including the Fiasp PumpCart®) to be non-preferred, to match previously placed Fiasp® products.</p> <p>And lastly, she recommended adding all Lyumjev® products (including the Lyumjev Tempo Pen®) to be non-preferred, to match previously placed Lyumjev® products.</p>																																					

V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
H.	For Possible Action: Discussion and possible adoption of Short-Intermediate Acting Insulins.																																						
I.	<u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody></tbody></table>		Yes	No	Abst.																																	
	Yes	No	Abst.																																				

	<ul style="list-style-type: none">• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Kate Ward, Pharm.D., Vice Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																					
IV. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended shifting Humulin N® vial, Humulin N Kwikpen®, and Humulin R® U-100 to preferred.																																					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
I. For Possible Action: Discussion and possible adoption of Long-Acting Insulins .																																						
I. Public Comment	Telephonic and web comments were called for, and the phone lines																																					

		were opened.																																					
		No public comment was provided.																																					
II.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
IV.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended removing Levemir® from the PDL, as this product has been discontinued.</p> <p>She also recommended adding insulin degludec (the generic for Tresiba® and Tresiba FlexTouch®) and insulin glargine (the generic for Toujeo® and Toujeo Max®) as non-preferred products.</p> <p>She also recommends placing the Basaglar Tempo Pen® as non-preferred as well.</p>																																					
V.	Discussion by Board and action by Board for	Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.																																					

approval of drugs for inclusion on the PDL.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
J. For Possible Action: Discussion and possible adoption of Pre-Mixed Insulin Combinations .																																						
I. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																																					

		<table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
IV.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended Keeping Humalog 75/25® vial as preferred, and non-prefering the Humalog 75/25 Kwikpen®.</p> <p>She also recommended placing the generic insulin lispro protamine/insulin lispro Kwikpen® as preferred.</p> <p>She also recommends adding insulin aspart/insulin aspart protamine vial and flexpen to preferred, and moving its associated branded product (Novolog 70/30®) to non-preferred.</p>																																					
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>									
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				

	<ul style="list-style-type: none">• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																	
K. For Possible Action: Discussion and possible adoption of Antivirals, COVID-19.																																		
I. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	
II. <u>Drug class review presentation by Prime.</u>	Dr. Deoliveira discussed Paxlovid. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.																																	
III. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended creating a new class on the PDL “Antivirals, COVID-19”, with Paxlovid® placed as a preferred product.																																	
IV. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

	<ul style="list-style-type: none">Aditi Singh, MD <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div>																																					
L. Drug class review presentation by Prime	Dr. Deoliveira discussed Topical Steroids. She presented the drug class and noted the indication, mechanism of action, and efficacy studies.																																					
M. For Possible Action: Discussion and possible adoption of Steroids, Topical Low.																																						
I. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																					
II. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
IV. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommends the preferred products to be: <ul style="list-style-type: none">hydrocortisone cream (topical and rectal), oint																																					

	<ul style="list-style-type: none">• hydrocortisone acetate cream, oint• hydrocortisone-aloe cream <p>And the non-preferred products to be:</p> <ul style="list-style-type: none">• Aclometasone dipropionate• Desonide• hydrocortisone lotion, gel• fluocinolone oil																																					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
N. For Possible Action: Discussion and possible adoption of Steroids, Topical Medium.																																						
I. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					

II.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
IV.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends the preferred products to be:</p> <ul style="list-style-type: none"> • fluocinolone acetonide soln • fluticasone propionate cream, oint • hydrocortisone valerate cream • mometasone furoate cream, oint, soln • Oralone® • triamcinolone paste <p>And the non-preferred products to be:</p> <ul style="list-style-type: none"> • betamethasone valerate foam • fluocinolone acetonide cream, oint • fluticasone propionate lotion • flurandrenolide • hydrocortisone butyrate cream, oint, soln, lipid/lipocream 																																					

	<ul style="list-style-type: none">hydrocortisone valerate ointprednicarbate																																					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
O. For Possible Action: Discussion and possible adoption of Steroids, Topical High.																																						
I. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic	Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Adashek seconded the motion.																																					

equivalency of agents in class.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
IV. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends the preferred products to be:</p> <ul style="list-style-type: none">• betamethasone dipropionate cream, oint, lotion• betamethasone dipropionate/prop gly cream• triamcinolone acetonide cream, oint, lotion• fluocinonide cream, oint, soln <p>And the non-preferred products to be:</p> <ul style="list-style-type: none">• betamethasone dipropionate gel• betamethasone dipropionate/prop gly lotion, oint• betamethasone valerate cream, lotion, oint• desoximetasone• diflorasone diacetate• fluocinonide emollient, gel• Halcinonide• Halog®• Topicort®• Vanos®																																					
V. Discussion by Board and action by Board for	Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Adashek seconded the motion.																																					

approval of drugs for inclusion on the PDL.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
P. For Possible Action: Discussion and possible adoption of Steroids, Topical Very High.																																						
I. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
II. Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
III. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																													
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none">• Kate Ward, Pharm.D., Vice Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>					
IV. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends the preferred products to be:</p> <ul style="list-style-type: none">• clobetasol propionate 0.05% cream• clobetasol propionate oint, gel, soln• halobetasol propionate oint, cream <p>And the non-preferred products to be:</p> <ul style="list-style-type: none">• Bryhali®• clobetasol lotion, shampoo, emollient• clobetasol propionate spray, foam• Clobex® shampoo• halobetasol propionate foam					
V. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Kate Ward, Pharm.D., Vice Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></tbody></table>		Yes	No	Abst.	
	Yes	No	Abst.			

	<ul style="list-style-type: none"> Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
Q. Prime Reports	<p>New Drugs to Market and New Line Extensions</p> <ul style="list-style-type: none"> On The Horizon: Notable FDA Decisions Expected (2Q2025) New respiratory drug: brensocatib New immunology drug: rilzabrutinib New neurology drug: vatiquinone 	
4. Closing Discussion		
A. Public comments on any subject	Public comments were provided by Amy Hale on behalf of Nevada Pharmacy Alliance.	
B. Date and location of the next meeting.	<p>Date: September 18, 2025</p> <p>Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109</p>	
C. Adjournment	Chairperson Decerbo adjourned the meeting at 3:14 PM.	

Attachment A – Members of the Public in Attendance

Ann Marie O'Toole	Jason	Thomas L. Beranek
Bobby White	Lea Cartwright	Nick Trombold
Alisa Cadenhead	Lisa Glick	Valerie D Ng
Corinne Copeland	Mandeep Sohal	Jason Smith
Leslie Costalin	Matthew Metcalf	Justin Clark
Eileen Zimmer	Lisa Pulver	Aaron Feyos
Eric Alonzo	Shirley Quach	Lee Stout
Dale Fisher	Rianna White	Stefanie Abraham
Adam Furman	Ryan A Roa	KJ Jackson
Amy Hale	Sabrina Schnur	Aaron Girvin

Attachment B – Submitted Written Comment

None